ArticleJournal for immunotherapy of cancer2025

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release.

Miguel Gaspar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.